D-1546-2022 Class III Terminated

Recalled by Leading Pharma, LLC — Fairfield, NJ

FDA drug recall D-1546-2022 was initiated by Leading Pharma, LLC on Aug 23, 2022 and is designated Class III. Reason for recall: Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules The recall status is terminated (terminated Sep 28, 2023). Affected quantity: 960 bottles (100 capsules).

Recall details

Product Type
Drugs
Report Date
Oct 5, 2022
Initiation Date
Aug 23, 2022
Termination Date
Sep 28, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
960 bottles (100 capsules)

Product description

ClomiPRAMINE Hydrochloride Capsules, USP 25mg, 100-count bottles, Rx only, LEADING PHARMA, Manufactured by: Leading Pharma, LLC, Fairfield, NJ 07004, NDC 69315-167-01

Reason for recall

Superpotent Drug: Assay value found to be 110.6% in Chlomipramine Hydrocholoride capsules

Distribution pattern

Nationwide within the United States

Code information

Lot#: B14221, Exp. Date 02/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1546-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1546-2022. Report a data issue: hello@regdatalab.com.